Similar Median OS Between Ripretinib versus Sunitinib in Patients with Advanced GIST While Safety More Favourable for Ripretinib By Ogkologos - June 2, 2025 692 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival and updated safety analysis of the INTRIGUE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Selpercatinib Shows Promise against Lung Cancers with Alterations in RET Gene September 27, 2019 Significantly Longer PFS with First-line Pembrolizumab for MSI-H/dMMR mCRC December 3, 2020 France Bans all Textured and Polyurethane Breast Implants Amid BIA-ALCL Cancer... April 5, 2019 Enfortumab Vedotin Approved for Recurrent Bladder Cancer January 14, 2020 Load more HOT NEWS Final DFS Analysis Demonstrates that Adjuvant Osimertinib Improves DFS in Patients... Oncology Dietitians Don’t Usually Inquire About Food Insecurity in Cancer Patients,... Perguntas frequentes sobre COVID-19 e câncer: respostas para pacientes e sobreviventes 10 Tips for National Cancer Prevention Month
